DE69526934T2 - Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere - Google Patents

Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere

Info

Publication number
DE69526934T2
DE69526934T2 DE69526934T DE69526934T DE69526934T2 DE 69526934 T2 DE69526934 T2 DE 69526934T2 DE 69526934 T DE69526934 T DE 69526934T DE 69526934 T DE69526934 T DE 69526934T DE 69526934 T2 DE69526934 T2 DE 69526934T2
Authority
DE
Germany
Prior art keywords
nitric oxide
releasing
delivery means
medicines
restenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526934T
Other languages
English (en)
Other versions
DE69526934D1 (de
Inventor
K Keefer
C Hutsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Comedicus Inc
Original Assignee
US Department of Health and Human Services
Comedicus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Comedicus Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69526934D1 publication Critical patent/DE69526934D1/de
Publication of DE69526934T2 publication Critical patent/DE69526934T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
DE69526934T 1994-03-17 1995-03-09 Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere Expired - Fee Related DE69526934T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/214,372 US5650447A (en) 1992-08-24 1994-03-17 Nitric oxide-releasing polymers to treat restenosis and related disorders
PCT/US1995/003040 WO1995024908A1 (en) 1994-03-17 1995-03-09 Use of nitric oxide-releasing polymers to treat restenosis and related disorders

Publications (2)

Publication Number Publication Date
DE69526934D1 DE69526934D1 (de) 2002-07-11
DE69526934T2 true DE69526934T2 (de) 2003-01-02

Family

ID=22798839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526934T Expired - Fee Related DE69526934T2 (de) 1994-03-17 1995-03-09 Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere

Country Status (11)

Country Link
US (1) US5650447A (de)
EP (1) EP0752866B1 (de)
JP (1) JPH10502905A (de)
AT (1) ATE218352T1 (de)
AU (1) AU698525B2 (de)
CA (1) CA2185457C (de)
DE (1) DE69526934T2 (de)
DK (1) DK0752866T3 (de)
ES (1) ES2177637T3 (de)
PT (1) PT752866E (de)
WO (1) WO1995024908A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
CA2206119C (en) * 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AU3986097A (en) * 1996-08-27 1998-03-19 University Of Akron, The Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US6372796B1 (en) * 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
AU5143300A (en) * 1999-05-21 2000-12-12 Micro Therapeutics, Inc. Methods for delivering in vivo uniform dispersed embolic compositions of high viscosity
US6645167B1 (en) 1999-05-21 2003-11-11 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an embolizing composition
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
WO2001010344A1 (en) * 1999-08-04 2001-02-15 C.R. Bard, Inc. Nitric oxide releasing medical devices
US7597698B2 (en) * 1999-08-10 2009-10-06 Maquet Cardiovascular Llc Apparatus and method for endoscopic encirclement of pulmonary veins for epicardial ablation
US7288096B2 (en) 2003-01-17 2007-10-30 Origin Medsystems, Inc. Apparatus for placement of cardiac defibrillator and pacer
US20040102804A1 (en) * 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
US6569082B1 (en) 1999-08-10 2003-05-27 Origin Medsystems, Inc. Apparatus and methods for cardiac restraint
US7398781B1 (en) * 1999-08-10 2008-07-15 Maquet Cardiovascular, Llc Method for subxiphoid endoscopic access
US20030187461A1 (en) * 1999-08-10 2003-10-02 Chin Albert K. Releasable guide and method for endoscopic cardiac lead placement
US7526342B2 (en) * 1999-08-10 2009-04-28 Maquet Cardiovascular Llc Apparatus for endoscopic cardiac mapping and lead placement
US20060287574A1 (en) * 1999-08-25 2006-12-21 Chin Albert K Longitudinal dilator
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
WO2001054748A1 (en) * 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
KR20030065463A (ko) 2000-08-11 2003-08-06 데이비드 알. 휘트록 질소 산화물 및 질소 산화물 전구체의 생산을 증가시키기위한 암모니아 산화 박테리아를 포함하는 조성물 및 이를이용하는 방법
US20050043506A1 (en) * 2000-09-27 2005-02-24 Michigan Biotechnology Institute Polyamide materials based on unsaturated carboxylic acids and amines
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
WO2002030487A2 (en) 2000-10-11 2002-04-18 Micro Thereapeutics, Inc. Methods for treating aneurysms
PT1328213E (pt) 2000-10-16 2005-10-31 Conor Medsystems Inc Dispositivo medico expansivel para a administracao de um agente benefico
US7049308B2 (en) * 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6565601B2 (en) 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
ATE319423T1 (de) * 2000-12-27 2006-03-15 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
CA2446064A1 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1436018A1 (de) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Stickoxid freisetzende beschichtete medizinprodukte und verfahren zu ihrer herstellung
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
EP1472021A4 (de) * 2002-01-11 2008-04-16 David R Whitlock Ammoniak oxidierende bakterien enthaltende zusammensetzungen und verwendungsverfahren dafür
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
US7204940B2 (en) 2002-03-20 2007-04-17 Michigan Biotechnology Institute Conductive polymer-based material
WO2003080039A1 (en) * 2002-03-21 2003-10-02 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
EP1507526A2 (de) * 2002-05-07 2005-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polydiazeniumdiolierte cyclische polyamine mit polyphasischer stickoxid-freisetzung und verwandte verbindungen, diese enthaltende zusammensetzungen und anwendungsverfahren dafür
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
WO2004012874A1 (en) 2002-08-02 2004-02-12 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Cross-linked nitric oxide-releasing polyamine coated substrates, compositions comprising same and method of making same
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
EP2272544A1 (de) 2003-03-28 2011-01-12 Conor Medsystems, Inc. Implantierbare medizinische Vorrichtung enthaltend eine therapeutische Substanz in einem Konzentrationsgradient.
CN104257454A (zh) * 2003-04-23 2015-01-07 阿克伦大学 附连的反应材料
EP1648826B1 (de) 2003-07-03 2017-08-23 The University Court of the University of St. Andrews Zeolithe zur freisetzung von stickstoffmonoxid
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1668008A4 (de) * 2003-08-28 2009-02-25 Nitromed Inc Nitrosierte und nitrosylierte diuretische verbindungen, zusammensetzungen und anwendungsverfahren
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2005067815A1 (en) * 2004-01-05 2005-07-28 Zygo Corporation Stage alignment in lithography tools
WO2005070008A2 (en) * 2004-01-22 2005-08-04 The University Of Akron Polymer no donor predrug nanofiber coating for medical devices and therapy
AU2005207037A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US20050165452A1 (en) * 2004-01-28 2005-07-28 Medtronic, Inc. Antithrombogenic medical device
EP1718603A4 (de) * 2004-02-09 2009-09-23 Noxilizer Inc Stickstoffmonoxid freisetzende moleküle
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
CA2581939C (en) 2004-09-27 2013-01-08 Joseph A. Hrabie Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
WO2006052899A2 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1690532A1 (de) * 2005-02-11 2006-08-16 NOLabs AB Vorrichtung zur Behandlung vom Magen und ihr Verfahren zur Herstellung
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
MX2007009690A (es) * 2005-02-11 2007-10-15 Nolabs Ab Dispositivo, metodo y uso para tratamiento de neuropatias que implican oxido nitrico.
EP1858863A1 (de) * 2005-02-28 2007-11-28 Nitromed, Inc. Stickstoffmonoxid-verstärkende gruppen enthaltende cardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1865770A4 (de) * 2005-04-07 2010-12-29 Nitromed Inc Beurteilung des genetischen risikos bei herzversagen: auswirkung der genetischen variation von nos3
EP1883614A4 (de) * 2005-05-23 2010-04-14 Nicox Sa Organische stickoxide verbessernde salze aus nichtsteroiden entzündungshemmenden verbindungen sowie zusammensetzungen und verwendungsverfahren dafür
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
WO2007005758A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Methods , compositions and devices for promoting angiogenesis
CA2613106A1 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Analyte sensors and compositions for use therein
WO2007005910A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Nitric oxide coatings for medical devices
EP1915157A4 (de) * 2005-08-02 2010-09-01 Nicox Sa Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
JP2009505727A (ja) * 2005-08-25 2009-02-12 メドトロニック ヴァスキュラー インコーポレイテッド 医療機器及びそのコーティングとして有益な一酸化窒素放出生分解性ポリマー
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
EP1945030A4 (de) * 2005-10-04 2009-10-21 Nitromed Inc Genetische risikobeurteilung bei herzversagen: einfluss der genetischen variation auf den gly389arg-polymorphismus des beta 1 adrenergen rezeptors
AU2006309212B2 (en) * 2005-10-31 2011-09-15 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
EP1954685A4 (de) * 2005-11-16 2009-11-11 Nitromed Inc Furoxanverbindungen, zusammensetzungen und anwendungsverfahren
EP1968664B1 (de) * 2005-12-02 2010-10-27 The Regents Of The University Of Michigan Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit
JP2009518516A (ja) * 2005-12-06 2009-05-07 アミュレット ファーマシューティカルズ インコーポレイティッド 一酸化窒素放出ポリマー
EP1968584A2 (de) * 2005-12-20 2008-09-17 Nitromed, Inc. Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
US8067414B2 (en) 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) * 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
WO2009064861A2 (en) * 2007-11-13 2009-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof
US20090170933A1 (en) * 2007-12-26 2009-07-02 Cook Incorporated Method for removing a medical device from a spasmodic constriction in a bodily passageway
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
CA2717867C (en) 2008-03-07 2017-05-30 Paul J. Shami Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
AU2010249558A1 (en) * 2009-05-20 2011-12-08 Arsenal Medical, Inc. Medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
EP2467127B1 (de) 2009-08-21 2023-08-02 Novan, Inc. Topische gele
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
US20110301299A1 (en) 2010-06-08 2011-12-08 Medtronic Vascular, Inc. Medical Devices and Polymers Therefor Having PTFE Surfaces Modified With Nitric Oxide-Releasing Polymers
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
WO2012153331A2 (en) 2011-05-09 2012-11-15 Topical Therapeutic Agent (Tta) Ltd. Nitric oxide-sequestering topical formulations
CN106456678A (zh) 2014-04-15 2017-02-22 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
EP3180366B1 (de) * 2014-08-14 2018-09-26 Rohm and Haas Company Polymer mit freisetzbarem gas
CA2975573C (en) 2015-02-03 2023-08-01 University Court Of The University Of St Andrews No containing compositions
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2018247167A1 (en) 2017-03-28 2019-09-26 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
CN111836648A (zh) 2018-03-06 2020-10-27 北卡罗来纳大学查佩尔希尔分校 作为可生物降解抗菌支架的一氧化氮释放型环糊精以及其相关方法
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法
WO2023081681A1 (en) * 2021-11-03 2023-05-11 Baxter International Inc. Nitric oxide donors for use in surgical recovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL151996B (nl) * 1971-04-15 1977-01-17 Snam Progetti Werkwijze voor de bereiding van gemodificeerde polymeren.
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5185376A (en) * 1991-09-24 1993-02-09 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
US5219710A (en) * 1991-11-25 1993-06-15 Allied-Signal Inc. Polymeric nitrones having a styrene-derived backbone chain

Also Published As

Publication number Publication date
DK0752866T3 (da) 2002-09-16
EP0752866A1 (de) 1997-01-15
AU1988995A (en) 1995-10-03
US5650447A (en) 1997-07-22
ATE218352T1 (de) 2002-06-15
WO1995024908A1 (en) 1995-09-21
ES2177637T3 (es) 2002-12-16
CA2185457A1 (en) 1995-09-21
DE69526934D1 (de) 2002-07-11
CA2185457C (en) 2004-05-25
JPH10502905A (ja) 1998-03-17
EP0752866B1 (de) 2002-06-05
PT752866E (pt) 2002-11-29
AU698525B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DE69526934T2 (de) Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE311867T1 (de) Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
ATE101515T1 (de) Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur behandlung der symptome der unenthaltsamkeit.
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE171869T1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
ATE232390T1 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
DE69623316T2 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
BR9808063A (pt) Métodos para tratamento de distúrbios vasculares.
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee